Skip to Main Content
  • Login
  • Contact Us
  • Donate

NANETS

  • About
    • Mission
    • Board of Directors
    • Committees
    • NANETS Presidents
    • Lifetime Achievement
    • Outstanding Service
    • History
    • Diversity Statement
  • Education
    • Virtual Programming Series
    • Upcoming Symposia
    • Regional NET Education
    • Conference Archives
    • NETMed Webinar Archives
    • About NETs
  • Research
    • Abstracts Library
    • Abstract Instructions
    • Research Grants
    • Grant Recipients
    • Grant Instructions
  • Guidelines
  • Resources
    • Grant Resources
    • Employment Postings
    • Clinical Trials
    • Member DirectoryMember Directory
    • NET Around the World
    • Patient Resources
    • Women in NETs
    • COVID-19 Resource Page
  • News
    • NET eNews
    • Media
    • PancreasPancreas
    • Photo Gallery
  • Membership
    • Member Login
    • Member Benefits
    • Member Categories
    • Join NOW
    • Code of Conduct
  • 2020

  • 2019

  • 2018

  • 2017

  • 2016

  • 2015

  • 2014

  • 2013

  • 2012

  • 2011

  • 2010

  • 2009

AB01 – PRRT 2.0: Definition and Prediction of Efficacy with Circulating Neuroendocrine Tumor Transcripts

Published in 2016 Listed under AB, Poster

Download

Bodei

  pdf Download Poster (872 KB)

AB02 – Circulating Neuroendocrine Gene Transcripts – the NETest – Accurately Identify GEP-NETs, Are Decreased by Surgery and Predict Tumor Progression and Recurrence

Published in 2016 Listed under AB, Poster

Download

Kidd

  pdf Download Poster (749 KB)

AB03 – A Prognostic Model for Pulmonary Carcinoid Tumors Based on Large Chromosomal Alterations

Published in 2016 Listed under AB

Download

Leventakos

AB04 – Blood Gene Transcript Analysis Diagnoses Bronchopulmonary NETs and Identifies Progressive Disease

Published in 2016 Listed under AB, Poster

Download

Lewczuk

  pdf Download Poster (924 KB)

AB05 – Neuroendocrine Tumor Blood Transcript Analysis, the NETest, Predicts Gastroenteropancreatic Neuroendocrine Tumor Disease Status and is Prognostic for Progressive Disease

Published in 2016 Listed under AB, Poster

Download

Pavel

  pdf Download Poster (932 KB)

AB06 – Next-Generation Sequencing (NGS) in Pancreatic Neuroendocrine Tumors (panNETs): Defining Differentiation and Grade Genetically

Published in 2016 Listed under AB, Poster

Download

Raj

  pdf Download Poster (481 KB)

B01 – Genomic Profiling Distinguishes Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (GEP-NEC) from Small Cell Lung Carcinoma (SCLC)

Published in 2016 Listed under Basic Science

Download

Bergsland

B02 – Correlation of Angiogenic Markers in Neuroendocrine Tumors and Their Prognostic Implications

Published in 2016 Listed under Basic Science, Poster

Download

Beyer

  pdf Download Poster (421 KB)

B03 – Immune Checkpoint Markers and Immune Response in Well Differentiated Neuroendocrine Tumors (NET) of the Small Intestine and Pancreas

Published in 2016 Listed under Basic Science

Download

da Silva

B04 – Loss of UCHL1 Expression Increases Metastatic Potential in Pancreatic Neuroendocrine Tumors

Published in 2016 Listed under Basic Science

Download

Finnerty

B05 – Development of Non-Metastatic and Metastatic Xenograft Models of Pancreatic Neuroendocrine Disease for Defining the Molecular Landscape Responsible for Progression and Therapeutic Outcome

Published in 2016 Listed under Basic Science

Download

Glenn

B06 – Met Activation Confers Increased Aggressiveness and Corresponds with Hypoenhancement on Contrast Enhanced Computed Tomography in Pancreatic Neuroendocrine Tumors

Published in 2016 Listed under Basic Science

Download

Krampitz

B07 – New Image-guided Alpha Particle Therapy for NETs in Children and Adults

Published in 2016 Listed under Basic Science

Download

Lee

B08 – Novel Combinatorial Drug Therapy for MTC

Published in 2016 Listed under Basic Science

Download

Pozo

B09 – Enhancing Neuroendocrine (NET) Cancer Therapy Responses via Disruption of Peroxide Balance

Published in 2016 Listed under Basic Science

Download

Rodman

B10 – RABL6A, A Novel Oncogene Required for Akt-mTOR and Myc Signaling in Pancreatic Neuroendocrine Tumor Cells

Published in 2016 Listed under Basic Science

Download

Sheehy

 

B11 – The 2nd Gen mTOR inhibitor INK128 Overcomes Resistance to Everolimus (1st Gen) in Pancreatic Neuroendocrine Tumors

Published in 2016 Listed under Basic Science

Download

Wang

B12 – The Pentarin Miniaturized Drug Conjugate PEN-221 Targets the Potent Cytotoxic DM1 To Somatostatin 2 Receptor Expressing Cancers

Published in 2016 Listed under Basic Science

Download

Whalen

B13 – Distinctive Chromosomal Instability (CIN) Patterns and its Prognostic Value in Pancreatic Neuroendocrine Tumors (pNET)

Published in 2016 Listed under Basic Science

Download

Yao

 

B14 – TR4: A Potential Therapeutic Target in NETs

Published in 2016 Listed under Basic Science

Download

Zhang

B15 – CgA Depletion Inhibits Neuroendocrine Tumor Cell Growth and Alters Phenotype

Published in 2016 Listed under Basic Science

Download

Zhang

C01 – Simulated-Use Study of a Single-Use Delivery Device for Lanreotide Depot in Untrained Health Care Professionals

Published in 2016 Listed under Clinical, Poster

Download

Adelman

  pdf Download Poster (5.41 MB)

C02 – Impact of Prior Somatostatin Analogue (SSA) Use on Progression-free Survival (PFS) in Patients with Advanced Nonfunctional Neuroendocrine Tumors (NET) of Lung or Gastrointestinal (GI) Origin: A Secondary Analysis from the RADIANT-4 Study

Published in 2016 Listed under Clinical

Download

Buzzoni

C03 – Escalated Dose Somatostatin Analogues (SSA) in Management of NETs: A Systematic Review

Published in 2016 Listed under Clinical

Download

Chan

C04 – Efficacy and Safety of Everolimus in Advanced, Progressive ,Nonfunctional Neuroendocrine Tumors (NET) of the Lung: A Subgroup Analysis of the Phase 3 RADIANT-4 Study

Published in 2016 Listed under Clinical, Poster

Download

Fazio

  pdf Download Poster (485 KB)

C05 – Efficacy of Lanreotide Depot/Autogel for Symptomatic Control of Carcinoid Syndrome (CS) in Neuroendocrine Tumor Patients: Follow-up Analysis of the ELECT Prospective, Randomized, Doubleblind and Open-label Phases

Published in 2016 Listed under Clinical, Poster

Download

Fisher, Jr

  pdf Download Poster (927 KB)

C06 – Pharmacokinetic (PK) Differences Between Subcutaneous and Intramuscular Administration of Lanreotide: Results from a Phase I Study

Published in 2016 Listed under Clinical, Poster

Download

Manon

  pdf Download Poster (2.26 MB)

C07 – Capecitabine and Temozolomide (C/T) Combination Therapy in Patients (pts) with Advanced Neuroendocrine Neoplasms (aNEN) and the Role of O6-methylguanine-methyltransferase (MGMT) as a Potential Biomarker for Response

Published in 2016 Listed under Clinical, Poster

Download

Owen

  pdf Download Poster (519 KB)

C08 – Efficacy and Safety Results of Telotristat Ethyl in Patients with Carcinoid Syndrome During the Double-blind Treatment Period of the TELECAST Phase 3 Clinical Trial

Published in 2016 Listed under Clinical

Download

Pavel

C09 – Impact of Prior Chemotherapy (Chemo) on Progression-free Survival (PFS) in Patients (Pts) with Advanced, Nonfunctional Lung or Gastrointestinal (GI) Neuroendocrine Tumors (NET): A Secondary Analysis from The Phase 3 RADIANT-4 Study

Published in 2016 Listed under Clinical

Download

Pommier

C10 – The Efficacy and Safety of Sunitinib in Patients with Advanced Well-differentiated Pancreatic Neuroendocrine Tumors

Published in 2016 Listed under Clinical

Download

Raymond

C11 – Lanreotide Autogel/Depot (LAN) Post-Octreotide Long-Acting Release (OCT) for Safe and Tolerable Treatment of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Published in 2016 Listed under Clinical, Poster

Download

Saif

  pdf Download Poster (669 KB)

C12 – Use of Alklyating Chemotherapy in High Grade Neuroendocrine Tumours: Evaluation of Real World Data

Published in 2016 Listed under Clinical

Download

Sathiyapalan

C13 – Everolimus for Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Gastrointestinal (GI) Tract: Efficacy and Safety from a RADIANT-4 Subgroup Analysis

Published in 2016 Listed under Clinical

Download

Singh

C14 – Phase I, Multi-center, Open-label, Dose-escalation Study of Pasireotide LAR (PAS) in Patients With Advanced Neuroendocrine Tumors (NET)

Published in 2016 Listed under Clinical

Download

Strosberg

C15 – Long-term Safety/Tolerability of Lanreotide Autogel/Depot (LAN) in Neuroendocrine Tumors (NETs) Patients with Carcinoid Syndrome (CS): The ELECT Long-term Open-label Extension

Published in 2016 Listed under Clinical, Poster

Download

Vinik

  pdf Download Poster (828 KB)

C16 – Everolimus (EVE) in Advanced, Nonfunctional, Well-differentiated Neuroendocrine Tumors (NET) of Gastrointestinal (GI) or Lung Origin: Second Interim Overall Survival (OS) Results From the RADIANT-4 Study

Published in 2016 Listed under Clinical

Download

Yao

C17 – Pitfalls in the Response Evaluation after Peptide Receptor Radionuclide Therapy with [177Lu-DOTA0,Tyr3]Octreotate

Published in 2016 Listed under Clinical

Download

Brabander

C18 – Long-term Efficacy, Survival and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors

Published in 2016 Listed under Clinical

Download

Brabander

C19 – Long-term Efficacy, Survival and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors

Published in 2016 Listed under Clinical

Download

Brabander

C20 – Tumor Growth Rate (TGR) in Intestinal/Pancreatic Neuroendocrine Tumors: Post hoc Exploratory Analysis of Data from the CLARINET Study

Published in 2016 Listed under Clinical, Poster

Download

Caplin

  pdf Download Poster (824 KB)

C21 – Evaluation of Uncinate Process Uptake on DOTA-TOC PET/MRI

Published in 2016 Listed under Clinical

Download

Hope

 

C22 – Peptide Receptor Radionuclide Therapy (PRRT) for Metastatic Neuroendocrine Tumors (NETs): A United States Experience

Published in 2016 Listed under Clinical

Download

Katona

C23 – Personalized Dosimetry Based Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors with 90Y-DOTATOC

Published in 2016 Listed under Clinical

Download

Menda

C24 – Magnetic Resonance Imaging of Neuroendocrine Tumor Hepatic Metastases: Evaluation of Lesion Conspicuity and Interobserver Agreement of Lesion Measurements on Various Sequences

Published in 2016 Listed under Clinical, Poster

Download

Morse

  pdf Download Poster (319 KB)

C25 – Improved Survival in Stage IV NETs Treated with High Dose I-131 MIBG is Predicted by Response at Initial Follow up and by Multiple Rounds of Therapy

Published in 2016 Listed under Clinical

Download

Morse

 

C26 – NETTER-1 Phase III in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotatate: Efficacy, Safety, QoL Results and Subgroup Analysis

Published in 2016 Listed under Clinical

Download

Strosberg

 

C27 – Does Receptor Status Impact Survival of Patients with Neuroendocrine Tumors?

Published in 2016 Listed under Clinical

Download

Wang

C28 – Prospective Experience with Routine SSTR2A Immunohistochemistry in Neuroendocrine Epithelial Neoplasms

Published in 2016 Listed under Clinical

Download

Alkapalan

 

C29 – Identification of Recurrence Predictors in Stage I-III Midgut NETs After Curative Surgery

Published in 2016 Listed under Clinical

Download

Cives

C30 – Multiple and Secondary Hormone Secretion in Patients with Metastatic Pancreatic Neuroendocrine Tumors

Published in 2016 Listed under Clinical

Download

Crona

C31 – Identification of Primary Tumors in Patients Presenting with Metastatic Gastroenteropancreatic Neuroendocrine Tumors

Published in 2016 Listed under Clinical

Download

Keck

C32 – Higher Tumor Grade in Neuroendocrine Tumor Metastases Negatively Impacts Survival

Published in 2016 Listed under Clinical

Download

Keck

C33 – Outcome of Surgical Resection after Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT) for Pancreatic Neuroendocrine Neoplasms: A Case-matched Analysis

Published in 2016 Listed under Clinical, Poster

Download

Partelli

  pdf Download Poster (1.16 MB)

C34 – Number of Positive Nodes and Their Localization Correlate with Recurrence in Pancreatic Neuroendocrine Neoplasms: Implications for Surgery, Staging and Surveillance

Published in 2016 Listed under Clinical, Poster

Download

Partelli

  pdf Download Poster (477 KB)

C35 – Liver Needle Biopsies are Poor Predictors of Histologic Tumor Grade for Midgut Neuroendocrine Tumors

Published in 2016 Listed under Clinical

Download

Ramirez

C36 – Outcomes for Patients with Surgically Resected Thymic Neuroendocrine Tumors

Published in 2016 Listed under Clinical

Download

Sceusi

C37 – Neoplasia in Patients with Atrophic Metaplastic Autoimmune Gastritis (AMAG): Screening and Surveillance Endoscopy Should Become Standard of Care

Published in 2016 Listed under Clinical

Download

Stashek

O01 – Addressing Neuroendocrine Tumour Related Emotional Issues

Published in 2016 Listed under Other

Download

Ardill

O02 – Evidence of Improved Survival when Patients are Referred on to a Specialist NET Clinic with Multidisciplinary Team Management

Published in 2016 Listed under Other

Download

Ardill

O03 – What Matters Most? An Exploration of Decision Criteria Considered by Patients with GEP-NET and Physicians Using Holistic Multi-Criteria Decision Analysis

Published in 2016 Listed under Other, Poster

Download

Goetghebeur

  pdf Download Poster (1.03 MB)

O04 – To Treat or Watch? Identifying Drivers of Decisions for Patients with GEPNET Using Reflective Multi-Criteria Decision Analysis

Published in 2016 Listed under Other

Download

Goetghebeur

O05 – A Case Series of 27 Primary Ovarian Neuroendocrine Tumors

Published in 2016 Listed under Other

Download

Heskel

O06 – Retrospective Chart Review of Antidepressant Use in Patients with Carcinoid Tumors

Published in 2016 Listed under Other, Poster

Download

Isenberg-Grzeda

  pdf Download Poster (254 KB)

O07 – Antidepressant Use in Patients with Carcinoid Tumors: Results of A Systematic Review

Published in 2016 Listed under Other, Poster

Download

Isenberg-Grzeda

  pdf Download Poster (383 KB)

O08 – Renal Neuroendocrine Tumors (rNETs): A Single-center Experience

Published in 2016 Listed under Other, Poster

Download

Scales

  pdf Download Poster (78 KB)

O09 – Identifying and Prioritising Gaps in Neuroendocrine Tumour Researchresults of the Delphi Consensus Project of the Commonwealth Neuroendocrine Tumour Research Collaboration (CommNETS)

Published in 2016 Listed under Other

Download

Segelov

O10 – The Clinicopathologic Characteristics of Primary Presacral Neuroendocrine Tumor: A Single Center Experience

Published in 2016 Listed under Other, Poster

Download

Yang

  pdf Download Poster (671 KB)

P01 – Economic Burden of Illness of Malignant Gastrointestinal Neuroendocrine Tumors (NET)

Published in 2016 Listed under P, Poster

Download

Cai

  pdf Download Poster (338 KB)

P02 – Economic Burden of Illness of Malignant Lung Neuroendocrine Tumors (NET)

Published in 2016 Listed under P, Poster

Download

Cai

  pdf Download Poster (352 KB)

P03 – Epidemiology of Gastrointestinal Neuroendocrine Tumors (GI-NET) in the US: Analysis of 2 Large Insurance Claims Databases

Published in 2016 Listed under P, Poster

Download

Cai

  pdf Download Poster (413 KB)

P04 – Epidemiology of Neuroendocrine Tumors (NET) of the Lung in the US: Analysis of 2 Large Insurance Claims Databases

Published in 2016 Listed under P, Poster

Download

Cai

  pdf Download Poster (462 KB)

P05 – Neuroendocrine Tumor Incidence Over 18 years: Kentucky Cancer Registry vs SEER

Published in 2016 Listed under P

Download

Chauhan

P06 – The Prognostic Value of Lymph Node Status and Extent of Lymphadenectomy in Pancreatic Neuroendocrine Tumors Confined to and Extending Beyond the Pancreas

Published in 2016 Listed under P, Poster

Download

Conrad

  pdf Download Poster (709 KB)

P07 – Comparative Study of Pulmonary and Extrapulmonary High Grade Neuroendocrine Carcinomas: A SEER Database Analysis of 210195 Cases

Published in 2016 Listed under P

Download

Dasari

P08 – Survival Trends of Neuroendocrine Tumors and Associated Prognostic Factors

Published in 2016 Listed under P

Download

Dasari

P09 – Understanding a Rare Disease’s Impact on Health Systems: A Population-Based Analysis of Patterns and Drivers of Costs for Neuroendocrine Tumors Costs

Published in 2016 Listed under P

Download

Hallet

 

P10 – Access to Care and Outcomes for Neuroendocrine Tumors: Does Socio-Economic Status Matter? A Population-based Analysis

Published in 2016 Listed under P

Download

Hallet

 

P11 – Health-related Quality of Life (HRQoL) in Patients with Advanced, Nonfunctional, Well-differentiated Gastrointestinal (GI) or Lung Neuroendocrine Tumors (NET) in the Phase 3 RADIANT-4 Trial

Published in 2016 Listed under P

Download

Pavel

P12 – Health-related Quality of Life (HRQoL) in Patients with Advanced Neuroendocrine Tumors (NET) by Tumor Origin in the Phase 3 RADIANT-4 Trial

Published in 2016 Listed under P

Download

Pavel

P13 – Treatment Patterns, Clinical Outcomes, and Health Care Resource Utilization in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors (mGEP-NETs)

Published in 2016 Listed under P

Download

Pulgar

 

P14 – Incidence and Prevalence of Neuroendocrine Tumors in the United States 1973-2012

Published in 2016 Listed under P

Download

Shen

P15 – Functional Status and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Among Elderly Patients

Published in 2016 Listed under P

Download

Shen

P16 – Association of Disease Progression, Health-related Quality of Life (HRQoL), and Utility in Patients with Advanced, Nonfunctional, Welldifferentiated Gastrointestinal (GI) or Lung Neuroendocrine Tumors (NET) in the Phase 3 RADIANT-4 Trial

Published in 2016 Listed under P

Download

Singh

T01 – Cisplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery

Published in 2016 Listed under T

Download

Eads

T02 – A Phase II Trial of LEE011 in Combination with Everolimus in the Treatment of Advanced Well Differentiated Neuroendocrine Tumors of Foregut Origin

Published in 2016 Listed under T

Download

Raj

T03 – SPINET: A Randomized, Double-blind, Placebo-controlled Phase III Study of Lanreotide Autogel/Depot (LAN) in Patients with Advanced Lung Neuroendocrine Tumors

Published in 2016 Listed under Poster, T

Download

Reidy-Lagunes

  pdf Download Poster (804 KB)

NANETS

136 Everett Rd | Albany, NY 12205
(650) 7NANETS | staff@nanets.net

Member Login

Twitter Facebook LinkedIn
  • Privacy Policy
  • |
  • Site Map

Copyright ©2021 ADG. All Rights Reserved | Web Design & Development by ADG Creative, a division of ADG.
ADG is a certified Women Owned Business.